Market Research Logo

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2016’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
    • The report reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics and enlists all their major and minor projects
    • The report assesses Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overview
    Therapeutics Development
    Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview
    Pipeline Products for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Development by Companies
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics under Investigation by Universities/Institutes
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Development by Companies
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Products under Investigation by Universities/Institutes
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development
    Aeolus Pharmaceuticals, Inc.
    Angion Biomedica Corp.
    Atox Bio Ltd.
    BCN Biosciences L.L.C.
    Bolder Biotechnology, Inc.
    Cellerant Therapeutics, Inc.
    Cellphire, Inc.
    Chrysalis BioTherapeutics, Inc.
    Cleveland BioLabs, Inc.
    Cumberland Pharmaceuticals, Inc.
    Diffusion Pharmaceuticals Inc.
    GNI Group Ltd.
    Humanetics Corporation
    INSYS Therapeutics, Inc.
    Meabco A/S
    Neumedicines Inc.
    Nohla Therapeutics Inc.
    Onconova Therapeutics, Inc.
    Original BioMedicals Co. Ltd.
    PharmaIN Corporation
    Pluristem Therapeutics Inc.
    RDD Pharma Ltd.
    Reata Pharmaceuticals, Inc.
    RedHill Biopharma Ltd.
    RxBio, Inc.
    SK Chemicals Co., Ltd.
    Soligenix, Inc.
    Stemedica Cell Technologies, Inc.
    Terapio Corporation
    Tonix Pharmaceuticals Holding Corp.
    Vida Therapeutics Inc.
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    A-02 - Drug Profile
    AB-103 - Drug Profile
    ABC-294640 - Drug Profile
    AEOL-10150 - Drug Profile
    AEOL-10171 - Drug Profile
    amifostine - Drug Profile
    Antisense RNAi Oligonucleotide for Influenza, Rheumatoid Arthritis and Radiation-Induced Fibrosis - Drug Profile
    AVMOC-001 - Drug Profile
    BB-3 - Drug Profile
    BBT-007 - Drug Profile
    BBT-015 - Drug Profile
    BBT-018 - Drug Profile
    BBT-059 - Drug Profile
    BCN-057 - Drug Profile
    BIO-300 - Drug Profile
    BMX-001 - Drug Profile
    BPC-2 - Drug Profile
    C-2E2 - Drug Profile
    C-2E5 - Drug Profile
    Cell Therapy for Acute Radiation Syndrome - Drug Profile
    cerium oxide - Drug Profile
    CLT-009 - Drug Profile
    Des-Asp Angiotensin 1 - Drug Profile
    Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile
    entolimod - Drug Profile
    EWA-001 - Drug Profile
    HSJ-0017 - Drug Profile
    JP4-039 - Drug Profile
    LGM-2605 - Drug Profile
    m-2A2 - Drug Profile
    molgramostim - Drug Profile
    monosodium luminol - Drug Profile
    NMIL-121 - Drug Profile
    omaveloxolone - Drug Profile
    ondansetron hydrochloride - Drug Profile
    ondansetron hydrochloride CR - Drug Profile
    Peptide to Agonize GHSR-1a for Acute Ischemic Stroke, Acute Radiation Syndrome, and Sepsis - Drug Profile
    pirfenidone - Drug Profile
    PLXR-18 - Drug Profile
    RDD-2007 - Drug Profile
    recilisib sodium - Drug Profile
    Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile
    Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile
    Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile
    Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile
    RES-529 - Drug Profile
    RP-239X - Drug Profile
    rusalatide acetate - Drug Profile
    Rx-100 - Drug Profile
    SGX-201 - Drug Profile
    SGX-202 - Drug Profile
    SKI-2162 - Drug Profile
    Small Molecule to Inhibit GSK-3 for Acute and Late Radiation Injury - Drug Profile
    Small Molecules for Radiation and Chemical Toxicity - Drug Profile
    Small Molecules for Radiation Toxicity - Drug Profile
    Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile
    ST-266 - Drug Profile
    ST-7 - Drug Profile
    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
    SY-303A - Drug Profile
    SY-513 - Drug Profile
    SYGN-305 - Drug Profile
    SYGN-399 - Drug Profile
    Thrombosomes - Drug Profile
    TPO-7630 - Drug Profile
    TPO-7640 - Drug Profile
    VEDA-1209 - Drug Profile
    VTI-1000 Series - Drug Profile
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016
    Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Investigation by Universities/Institutes, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences L.L.C., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cumberland Pharmaceuticals, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corporation, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by INSYS Therapeutics, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co. Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corporation, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co., Ltd., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Terapio Corporation, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Vida Therapeutics Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..1), H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..2), H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..3), H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects (Contd..4), H2 2016
    Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H2 2016
    Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report